Multiple Sclerosis

NEUROLOGY 19m 3s Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review JAMA Neurology

NEUROLOGY 36m 35s 0.5 Credit CME Multiple Sclerosis Lecture Series: Treatment Stanford Medicine

NEUROLOGY 39m 25s 0.75 Credit CME Multiple Sclerosis Lecture Series: Novel Therapies Stanford Medicine

NEUROLOGY 33m 42s 0.5 Credit CME Multiple Sclerosis Lecture Series: Current Concepts Stanford Medicine

DEMYELINATING DISORDERS 1 Credit CME Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review JAMA Neurology

NEUROLOGY 1m 2s Brain Fluid-Attenuated Inversion Recovery (FLAIR) Magnetic Resonance Imaging (MRI) JAMA Otolaryngology–Head & Neck Surgery

NEUROLOGY 3m 44s What Is Multiple Sclerosis? JN Learning

NEUROLOGY 38m 40s 0.75 Credit CME Multiple Sclerosis Lecture Series: Diagnosis Stanford Medicine

NEUROLOGY 30m 15s 0.5 Credit CME Stanford Medcast Episode: Hot Topics Mini-Series - Stem Cell Therapy in Multiple Sclerosis Stanford Medicine

NEUROLOGY 30m 36s 0.5 Credit CME Stanford Medcast Episode: Hot Topics Mini-Series - Gut Microbiome in Multiple Sclerosis Stanford Medicine

NEUROLOGY 34m 57s 0.5 Credit CME Multiple Sclerosis Lecture Series: MS 101 Stanford Medicine

NEUROLOGY 31m 51s 0.5 Credit CME Stanford Medcast: Hot Topics Mini-Series – The Role of Epstein-Barr Virus in Multiple Sclerosis Stanford Medicine

VACCINATION 1 Credit CME Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab JAMA Neurology

VACCINATION 1 Credit CME Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis JAMA Neurology

VACCINATION 1 Credit CME Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab JAMA Neurology

NEUROLOGY 1 Credit CME Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden JAMA Network Open

DEMYELINATING DISORDERS 1 Credit CME Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Association of a Marker of N -Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration JAMA Neurology